BRCA2 and neoplasm: Compared to the BRCA1/2-like classifier, RECAP identified ten extra tumors as HRD, among which were four bi-allelic BRCA deficient tumors: one tumor (M096) with a somatic BRCA1/2 mutation, three tumors (M119, M141, and M277) with BRCA1 promoter methylation, as well as one tumor with a BRCA2 VUS and five BRCA wild-type tumors.